Aquavit Files Investigation of New Drug for New Botulinum Toxin
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
A team of facial plastic surgeons will operate on war-related facial trauma cases and train local doctors as part of its fourth medical mission in Ukraine.